Associated clinical characteristics of patients with candidemia among different Candida species

Journal of Microbiology, Immunology and Infection

Volumn 46, Issue 6, 2013, Pages 463-468

  Chen, Liang Yu ^a,b   Kuo, Shu Chen ^a,b   Wu, Hau Shin ^a   Yang, Su Pen ^a,b   Chan, Yu Jiun ^a,b   Chen, Liang Kung ^a,b   Wang, Fu Der ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Candidemia; Non albicans Candida species; Time to positivity; Total parenteral nutrition

Indexed keywords

ALBUMIN; AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CLAVISPORA LUSITANIAE; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNGAL VIRULENCE; FUNGUS IDENTIFICATION; HEALTH CARE COST; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TOTAL PARENTERAL NUTRITION; TRICHOSPORON ASAHII;

CANDIDEMIA; NON-ALBICANS CANDIDA SPECIES; TIME TO POSITIVITY; TOTAL PARENTERAL NUTRITION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANDIDA; CANDIDEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TAIWAN; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84890120392     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.08.001     Document Type: Article

References (37)

1. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
2. Tsai C.C., Wang C.C., Kuo H.Y., Chiang D.H., Lin M.L., Liu C.Y., et al. Adult candidemia at a medical center in northern Taiwan: a retrospective study. J Microbiol Immunol Infect 2008, 41:414-421.
3. Chen Y.C., Chang S.C., Sun C.C., Yang L.S., Hsieh W.C., Luh K.T. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997, 18:369-375.
4. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
5. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
6. Bassetti M., Righi E., Costa A., Fasce R., Molinari M.P., Rosso R., et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 6:21.
7. Davis S.L., Vazquez J.A., McKinnon P.S. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007, 41:568-573.
8. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and invitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39:3254-3259.
9. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
10. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
11. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
12. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377.
13. Bassetti M., Mikulska M., Viscoli C. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 2010, 14:244.
14. Moran C., Grussemeyer C.A., Spalding J.R., Benjamin D.K., Reed S.D. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J 2009, 28:433-435.
15. Playford E.G., Marriott D., Nguyen Q., Chen S., Ellis D., Slavin M., et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008, 36:2034-2039.
16. Leroy O., Mira J.P., Montravers P., Gangneux J.P., Lortholary O. Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010, 14:R98.
17. Chow J.K., Golan Y., Ruthazer R., Karchmer A.W., Carmeli Y., Lichtenberg D.A., et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008, 36:1993-1998.
18. Bone R.C., Sprung C.L., Sibbald W.J. Definitions for sepsis and organ failure. Crit Care Med 1992, 20:724-726.
19. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
20. Vincent J.L., Ferreira F., Moreno R. coring systems for assessing organ dysfunction and survival. Crit Care Clin 2000, 16:353-366.
21. Clinical and Laboratory Standards Institute Minutes of the subcommittee on Antifungal Susceptibility Testing meeting 2010, Clinical and Laboratory Standards Institute, Atlanta, GA.
22. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
23. Rodriguez D., Almirante B., Cuenca-Estrella M., Rodriguez-Tudela J.L., Mensa J., Ayats J., et al. Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect 2010, 16:1676-1682.
24. Sampaio Camargo T.Z., Marra A.R., Silva C.V., Cardoso M.F., Martino M.D., Camargo L.F., et al. Secular trends of candidemia in a tertiary care hospital. Am J Infect Control 2010, 38:546-551.
25. Hobson R.P. The global epidemiology of invasive Candida infections-is the tide turning?. J Hosp Infect 2003, 55:159-168.
26. Ben-Ami R., Weinberger M., Orni-Wasserlauff R., Schwartz D., Itzhaki A., Lazarovitch T., et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008, 46:2222-2226.
27. Fernandez J., Erstad B.L., Petty W., Nix D.E. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 2009, 64:402-407.
28. Horvath L.L., George B.J., Murray C.K., Harrison L.S., Hospenthal D.R. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. J Clin Microbiol 2004, 42:115-118.
29. Knaus W.A., Wagner D.P., Draper E.A., Zimmerman J.E., Bergner M., Bastos P.G., et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100:1619-1636.
30. Arendrup M., Horn T., Frimodt-Moller N. Invivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 2002, 30:286-291.
31. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ng K.P., Colombo A., et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008, 46:842-849.
32. Trofa D., Gácser A., Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21:606-625.
33. Krcmery V., Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260.
34. Wingard J.R. Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115-125.
35. Blot S., Vandewoude K., Hoste E., Poelaert J., Colardyn F. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. J Hosp Infect 2001, 47:308-313.
36. Safdar A., Bannister T.W., Safdar Z. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. Int J Infect Dis 2004, 8:180-186.
37. Jamal W., Tamaray G., Pazhoor A., Rotimi V.O. Comparative evaluation of BacT/ALERT 3D and BACTEC systems for the recovery of pathogens causing bloodstream infections. Med Princ Pract 2006, 15:223-227.